Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMDW) Change in Cash (2019 - 2025)

Historic Change in Cash for Revolution Medicines (RVMDW) over the last 7 years, with Q3 2025 value amounting to -$184.1 million.

  • Revolution Medicines' Change in Cash fell 14674.1% to -$184.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.2 million, marking a year-over-year increase of 11158.71%. This contributed to the annual value of -$152.4 million for FY2024, which is 12843.44% down from last year.
  • Revolution Medicines' Change in Cash amounted to -$184.1 million in Q3 2025, which was down 14674.1% from $69.1 million recorded in Q2 2025.
  • Revolution Medicines' Change in Cash's 5-year high stood at $342.6 million during Q4 2024, with a 5-year trough of -$407.7 million in Q1 2024.
  • For the 5-year period, Revolution Medicines' Change in Cash averaged around $6.2 million, with its median value being -$17.5 million (2022).
  • Over the last 5 years, Revolution Medicines' Change in Cash had its largest YoY gain of 255438.6% in 2023, and its largest YoY loss of 66735.27% in 2023.
  • Quarter analysis of 5 years shows Revolution Medicines' Change in Cash stood at -$20.0 million in 2021, then rose by 12.37% to -$17.5 million in 2022, then skyrocketed by 2030.45% to $338.4 million in 2023, then grew by 1.25% to $342.6 million in 2024, then crashed by 153.72% to -$184.1 million in 2025.
  • Its Change in Cash stands at -$184.1 million for Q3 2025, versus $69.1 million for Q2 2025 and -$209.5 million for Q1 2025.